Attention #AAIC2023 attendees, join us today as Combinostics CEO Lennart Thurfjell and Professor Linus Jönsson from Karolinska Institutet, delve into the intriguing topic of "The role of software tools and AI in the context of new disease modifying drugs in AD.
🌟 Exciting times at AAIC 2023! Our team is having a great first day showcasing Combinostics' imaging and decision support solutions for Dementia care. Don't miss your chance to learn more at booth 414!
1 week to go until Combinostics CEO, Lennart Thurfjell, and Professor Linus Jönsson from Karolinska Institutet delve into the role of AI in the context of new disease-modifying drugs for Alzheimer's Disease at #AAIC2023. Join them on July 18th, from 12:30 – 1:15.
Can you believe it's already the last day of #SNMMI2023? We've had an amazing time in Chicago discussing the latest in #FDGPET and #AmyloidPET quantification. If you haven't stopped by booth 3016 yet, now is your last chance to join the conversation. See you there!
📢 #SNMMI2023 attendees! 📢
Make sure to swing by booth 3016 to meet our amazing team and learn all about amyloid PET quantification and more! Our experts are eager to share their knowledge and answer any questions you may have. See you there!
#PETimaging#NuclearMedicine
Attention all #SNMMI2023 attendees in Chicago! Don't miss out on the chance to visit Combinostics at booth 3016 and learn about our upcoming PET quantification* solution. See you there!
https://t.co/mLL1xUZT6i
#PET#NuclearMedicine#Combinostics *Regulatory clearance pending
Combinostics is proud to be part of the @IHI_PROMINENT consortium, working together to create a digital platform for precision medicine that will improve the lives of patients with neurodegenerative diseases. #digitalhealth#neurodegeneration@IHIEurope
https://t.co/6U2UePY12U
Here, researchers, including our medical advisor, @FBarkhof, found that amyloid PET early in a diagnostic workup supported an etiological diagnosis with very high confidence after only 3 months, indicating its usefulness in clinical practice.
https://t.co/zxsEwX1iSh
More exciting news: The Phase 3 trial of donanemab met its primary endpoint and all secondary endpoints, showing promise for its ability to slow cognitive and functional decline in people with early symptomatic Alzheimer's disease.
https://t.co/ygJ6pkFJCN
Are you at #röko2023 today?
Don't miss the Combinostics Presentation from Elena Bonke!
Supporting the entire patient pathway: Early detection, diagnosis, and ongoing management of Alzheimer’s disease and other major neurological disorders
2:45 – 3:00 pm
See you there!
Attending the 104th German X-ray Congress (Deutscher Röntgenkongress) #röko2023?
Reserve time with our EU Team and stand by Combinostics' Booth: Süd 36.
See you there!
https://t.co/JYnxB5xmiP
#radiology#röko
Welcome to our new Clinical Application Specialist in Europe – Elena Bonke.
Elena is passionate about pioneering breakthroughs in healthcare by bridging the gap between clinical application and technical advancements.
Happy to have you on board!
Watch the new Combinostics webinar as Dr. Kevin Berger explores what you need to know about #MRI quantification of #MS and #Dementia cases!
The link is here:
https://t.co/OAaxCkG4lk
Thanks to everyone who joined Richard's Presentation today!
You always can schedule the online Demo with our team.
Also, don't forget about our 10-DAY FREE TRIAL to use the benefits of cMRI on your own patient cases!
It only takes minutes to start:
https://t.co/tPf83JOyC8
Are you at Advanced MRI today?
Welcome to The Combinostics' Presentation:
"Next level MRI Quantification and Dementia Treatment Pathway Support".
Richard Hausmann, CEO
Today, at 12:10